Cigna (CI, $150.56) is "compelling" , says Citigroup analysts
According to a group of Citigroup analysts, Cigna is "one of the most compelling stocks and stories" they have seen across 20 years on the sell side.
The group of analysts feels that the health services company has the right goals coupled with a strong historical performance, a solid strategy, improved positioning, and a balanced growth outlook – while having a low valuation.
Analyst Ralph Giacobbe mentioned that Cigna is trading at a 27% discount to peers and 49% discount to the market.
Citigroup gave Cigna shares a “buy” rating. It set a $203 target price on the shares, which would be 11 times the 2020 estimate. The target indicates upside of 31% from Wednesday's close price.
However, Giacobbe did mention that the outlook is not without a few risks, such as a potential unexpected increase in healthcare-costs, heated competition from peers, the risks inherent in integrating Express Scripts, and general headline risks from the focus on drug pricing and the evolving pharmacy-benefit-manager model.
CI in upward trend: 10-day moving average crossed above 50-day moving average on July 01, 2025
The 10-day moving average for CI crossed bullishly above the 50-day moving average on July 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 11, 2025. You may want to consider a long position or call options on CI as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CI just turned positive on June 09, 2025. Looking at past instances where CI's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in of 349 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 272 cases where CI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CI moved out of overbought territory on July 02, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where CI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
CI moved below its 50-day moving average on July 02, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CI broke above its upper Bollinger Band on June 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.234) is normal, around the industry mean (3.063). P/E Ratio (20.936) is within average values for comparable stocks, (17.509). Projected Growth (PEG Ratio) (0.928) is also within normal values, averaging (1.089). Dividend Yield (0.014) settles around the average of (0.020) among similar stocks. P/S Ratio (0.554) is also within normal values, averaging (0.684).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health insurance services
Industry ManagedHealthCare
Advertisement